Atypical teratoid/rhabdoid tumours (AT/RTs) are a very rare but aggressive type of cancer that usually affects very young children, often under the age of three. Because these tumours grow quickly and are hard to treat, there is an urgent need for new therapies.
Treating brain tumours is especially challenging because of the blood‑brain barrier—a natural protective shield that prevents many drugs from reaching the tumour.
Researcher Jessica Alyas is working on new treatment options for AT/RT. Her project focuses on two promising approaches:
Antibody‑drug conjugates (ADCs): medicines designed to deliver cancer‑killing drugs directly to tumour cells.
Tyrosine kinase inhibitors: drugs that block signals cancer cells use to grow, targeting a group of proteins called the HER family.
To find new drugs for a childhood cancer with limited treatment options and poor outcomes